122 related articles for article (PubMed ID: 32459381)
21. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Bass AKA; El-Zoghbi MS; Nageeb EM; Mohamed MFA; Badr M; Abuo-Rahma GEA
Eur J Med Chem; 2021 Jan; 209():112904. PubMed ID: 33077264
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
23. Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects.
Rodrigues DA; Pinheiro PSM; Fraga CAM
ChemMedChem; 2021 Feb; 16(3):448-457. PubMed ID: 33049098
[TBL] [Abstract][Full Text] [Related]
24. The value of a panel of circulating microRNAs in screening prostate cancer.
Sun C; Lu C; Li X; Li R; Wen Z; Ge Z; Chen W; Li Y; Sun S; Yang Q; Tao L; Li H; Lai Y
Transl Cancer Res; 2024 Feb; 13(2):686-698. PubMed ID: 38482417
[TBL] [Abstract][Full Text] [Related]
25. Quatramer™ encapsulation of dual-targeted PI3-Kδ/HDAC6 inhibitor, HSB-510, suppresses growth of breast cancer.
Tiwari S; Liu S; Anees M; Mehrotra N; Thakur A; Tawa GJ; Grewal G; Stone R; Kharbanda S; Singh H
Bioeng Transl Med; 2023 Sep; 8(5):e10541. PubMed ID: 37693068
[TBL] [Abstract][Full Text] [Related]
26. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
[TBL] [Abstract][Full Text] [Related]
27. HDAC-an important target for improving tumor radiotherapy resistance.
Ling R; Wang J; Fang Y; Yu Y; Su Y; Sun W; Li X; Tang X
Front Oncol; 2023; 13():1193637. PubMed ID: 37503317
[TBL] [Abstract][Full Text] [Related]
28. Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges.
Sorrentino C; Di Carlo E
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296848
[TBL] [Abstract][Full Text] [Related]
29. The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D; Cornice J; Arboretto P; Vecchiotti D; Di Vito Nolfi M; Capece D; Zazzeroni F; Franzoso G
Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140335
[TBL] [Abstract][Full Text] [Related]
30. Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.
Pramanik SD; Kumar Halder A; Mukherjee U; Kumar D; Dey YN; R M
Front Chem; 2022; 10():948217. PubMed ID: 36034650
[TBL] [Abstract][Full Text] [Related]
31. From Therapy Resistance to Targeted Therapies in Prostate Cancer.
Moreira-Silva F; Henrique R; Jerónimo C
Front Oncol; 2022; 12():877379. PubMed ID: 35686097
[TBL] [Abstract][Full Text] [Related]
32. HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.
Biersack B; Nitzsche B; Höpfner M
Cancer Drug Resist; 2022; 5(1):64-79. PubMed ID: 35582529
[TBL] [Abstract][Full Text] [Related]
33. Establishment of a Cell Model for Dynamic Monitoring of Intracellular Calcium Concentration and High-Throughput Screening of P2Y2 Regulators.
Wu M; Hu C; Liu J; Wu C; Liu X; Hao F; Li W
Molecules; 2022 May; 27(9):. PubMed ID: 35566353
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.
Yu H; Wu S; Liu S; Li X; Gai Y; Lin H; Wang Y; Edwards H; Ge Y; Wang G
J Cell Mol Med; 2022 May; 26(9):2646-2657. PubMed ID: 35355406
[TBL] [Abstract][Full Text] [Related]
35. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.
Chilamakuri R; Agarwal S
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205815
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression.
Xu P; Wang Y; Deng Z; Tan Z; Pei X
Oncol Lett; 2022 Feb; 23(2):67. PubMed ID: 35069876
[TBL] [Abstract][Full Text] [Related]
37. Sparstolonin B exerts beneficial effects on prostate cancer by acting on the reactive oxygen species-mediated PI3K/AKT pathway.
Liu S; Hu J; Shi C; Sun L; Yan W; Song Y
J Cell Mol Med; 2021 Jun; 25(12):5511-5524. PubMed ID: 33951324
[TBL] [Abstract][Full Text] [Related]
38. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?
Szumilak M; Wiktorowska-Owczarek A; Stanczak A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946916
[TBL] [Abstract][Full Text] [Related]
39. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
[TBL] [Abstract][Full Text] [Related]
40. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
